Liat Ben-Senior MBA MSc

Despite spectacular breakthroughs in human molecular genetics and information technologies, experts at McGill University show that #pharmacogenetic (PGx) testing in approved #cardiovasculardrugs is limited. As pre-emptive PGx combining genomic profiling with electronic medical records offers significant potential for improving healthcare, more research is needed to validate PGx markers. Read the article here: https://lnkd.in/e_43cSgm. #CVD #PharmacologicalReviews #pharmacology 

8

At SciTech, we're driven by a singular goal: to revolutionize cancer treatment for a wider range of patients. Our lead drug candidate, ST-001, is initially focused on T-cell non-Hodgkin's lymphoma (T-cell NHL) and small cell lung cancer (SCLC). However, the science behind ST-001 holds promise for a broader fight. Why so many targets? Fenretinide, the active ingredient in ST-001, has shown promise in past studies for various other cancers, including breast, cervical, colorectal, head & neck, leukemia, ovarian, kidney, pancreatic, and prostate cancers. We're committed to exploring the full potential of ST-001 and contributing to a future where thriving after cancer is possible for more patients. #scitechSDP #scitechdevelopment #oncology #nanofenretinide #fenretinide #lymphoma #nonhodgkin #drugdelivery #ST001

7

Korro will be participating in the 20th Annual Meeting of the Oligonucleotide Therapeutics Society, which will take place in Montreal from October 6-9.   Venkat Krishnamurthy, Ph.D., our Senior Vice President, Head of Platform, will deliver a presentation on KRRO-110, targeting alpha-1 antitrypsin deficiency (#AATD).   Oral Presentation Details: Title: KRRO-110, an RNA Editing Oligonucleotide For The Treatment Of Alpha-1 Antitrypsin Deficiency (AATD) When: Monday, October 7, 3:20 PM ET   We’re also proud to share two poster presentations by our scientists:   Agya Karki, Ph.D. will present on the purification of human ADAR for evaluating oligo-directed RNA editing (Poster #P133).   Zhiji Ren, Ph.D. will discuss on-target and off-target behaviors of RNA editing oligonucleotides using ADAR1 chimeric eCLIP (Poster #P228).   Learn more: https://lnkd.in/ef2FRJaX #OTS2024 #OligoMeeting #OligoTherapeutics #Oligonucleotide #RNAEditing

118

4 Comments

Exciting News at Innovation Network Canada!    We are thrilled to welcome Dr. Colin Collins, PhD as our new Chief Genomics Officer. With a distinguished career in genomics and cancer, Dr. Collins brings unparalleled expertise to our team.   Dr. Collins has been a driving force in the fields of genome and cancer research, particularly in the areas of prostate cancer genomics. His work has been instrumental in advancing our understanding of cancer biology and developing innovative therapeutic approaches. As the head of the Laboratory for Advanced Genome Analysis at the Vancouver Prostate Centre, he has led numerous groundbreaking studies that have had a profound impact on our understanding of prostate cancer.   At Innovation Network Canada, Dr. Colin Collins, PhD will lead our genomics initiatives, helping to shape the future of personalized medicine and drive transformative change in healthcare. His deep knowledge and innovative mindset will be invaluable as we continue to push the boundaries of what’s possible in the field of genomics.   Please join us in welcoming Dr. Collins to our team! We are excited about the incredible work we will accomplish together. #Genome Analysis #Genomics #AI #QuantumComputing #HealthcareInnovation #PrecisionMedicine #CancerResearch #PersonalizedMedicine #Biotechnology #LifeSciences #Innovation #holisticApproach #MultidisciplinaryInnovation #HealthcareLeadership #MedicalResearch #GenomicMedicine #DigitalHealth #HealthcareTransformation #HealthTech #ResearchAndDevelopment #Vancouver #BritishColumbia #BC #Canada #SustainableDevelopmentGoals #GlobalCollaboration #Global May Siksik Ray Simkus Urs Ribary Alex Khan

10

3 Comments

📘 New publication! CARB-X product developer Trellis Bioscience Inc. completed a first-in-human phase 1 clinical study that supports the further development of TRL1068 for the treatment of biofilm-associated infections, including medical device-associated infections and bacteremia. TRL1068 is a native human monoclonal antibody that disrupts bacterial biofilms with broad-spectrum activity against both Gram-positive and Gram-negative species. Evidence of efficacy, safety and pharmacokinetic data from this phase 1 study will help guide future phase 2 and 3 studies of TRL1068. 🔗 Read here: bit.ly/3LM3Avb #AMR #StopSuperBugs #SuperBugs #AntibioticResistance #Medicine #GlobalHealth #ProductDevelopment #Innovation #Biotechnology 

42

1 Comment

British Columbia's Biosimilars Initiative has successfully saved about $732 million over five years by transitioning over 40,000 patients from reference biologics to biosimilars, without compromising health outcomes. This incredible achievement was not merely due to changing prescriptions, but thanks to a comprehensive program for patients and physicians. Key aspects of the initiative included: 🔄 6-month transition period 📜 A requirement for a new prescription from a prescriber for the switch 💬 Support fees for prescribers and pharmacists assisting patients 📝 Patient lists for prescribers 🔍 Consultations with patient groups, clinicians, professional bodies, insurers, and drug sponsors 📚 Educational and support tools for patients and healthcare providers 📢 Coordinated communications 📊 Monitoring biosimilar utilization ❗Exceptional coverage for patients unable to switch for clinical reasons ⛔ Delisting reference biologics after the transition period With adoption rates of 91%-95% within 24 months, BC's model exemplifies effective biosimilar adoption for cost savings and improved patient care, setting a precedent for other regions. Explore how we integrate patient insights into clinical trials and healthcare solutions: >> https://lnkd.in/dtgXSjVm >> https://lnkd.in/dc4kXmjw #biosimilars #patients #clinicalresearch #clinicaltrials #healthcare #biotech

16

1 Comment

JSI Advanced Therapeutics Research Inc. (JATRI) is at the forefront of innovative therapeutic research, utilizing advanced facilities at Western Discovery Park and a team of scientists adept at tackling complex synthesis challenges. Our current research emphasizes the development of cyclic peptides, biodegradable lipids, and naturally occurring cyclic polyynes, utilizing our proprietary ring-closing metathesis reaction protocol. We also specialize in inhibitors, including USP7 inhibitors, Bruton Tyrosine Kinase inhibitors, and JAK inhibitors. In this discussion, we will focus on our ongoing research into VHL ligands for targeted protein degradation and their crucial role in PROTAC development. Please consult the list of VHL ligands included in the following pages. If you need support with therapeutic discovery and development or specialty chemicals, our affiliate companies—JSSI Specialty Chemicals and JSI Research Chemicals Inc.—are ready to assist. We also welcome opportunities for collaboration on contract research projects related to drug discovery and development. Additionally, we offer expertise in synthesizing biodegradable polymers and resins for your coating needs. Let’s explore how we can collaborate to advance your objectives in pharmaceuticals and beyond.

1